Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2020

Open Access 01-12-2020 | Obesity | Research article

The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients’ stratification by body mass index and age

Authors: Ana Podbregar, Andrej Janez, Katja Goricar, Mojca Jensterle

Published in: BMC Endocrine Disorders | Issue 1/2020

Login to get access

Abstract

Background

The escalating prevalence of adrenal incidentaloma (AI) has been associated with the improvement of radiologic techniques and widespread imaging in aging population. It is currently unclear whether patients with obesity more likely develop AI and the current rise in the prevalence of AI could be at least partly associated with the respective rise in obesity. We compared the prevalence and characteristics of non-functional (NF) and autonomous cortisol secreting (ACS) adrenal incidentalomas (AIs) after the study population was stratified by different body mass indexes (BMI) and age groups.

Methods

Retrospective cross-sectional study comprising of 432 patients (40.6% male, 59.4% female) with NFAI (N = 290) and ACS (N = 142), of median age 63.4 (54.0–71.6) years and median BMI 28.6 (25.5–31.7) kg/m2. The data collection contained 11.132 points including demographic, anthropometric, radiologic, hormonal and metabolic parameters.

Results

We observed 68–87% higher prevalence of AI across different age groups in NFAI and ACS in obese/overweight compared to normal weight subjects. Patients with ACS were older (P = 0.008), with higher basal cortisol (P < 0.001), lower basal DHEAS (P = 0.001), lower suppression DHEAS (P = 0.027) and higher aldosterone (P = 0.039). AIs with ACS were larger than NFAI (P < 0.001). Interestingly, ACS group had lower body mass (P = 0.023) and did not differ in BMI, blood pressure, heart rate, lipid profile, fasting glucose and presence of diabetes mellitus type 2 when compared to NFAI., By contrast to the similarity of metabolic profiles in ACS and NFAI, some components of adverse metabolic traits were rather associated with higher BMI and older age, in particular in NFAI.

Conclusion

The prevalence of NFAI and ACS were significantly higher in overweight/obese subgroup across the age distribution. Stratification by age and BMI displayed significant differences in some metabolic traits, in particular in NFAI.
Literature
1.
go back to reference Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175(2):G1–G34.PubMed Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175(2):G1–G34.PubMed
2.
go back to reference Singh PK, Buch HN. Adrenal incidentaloma: evaluation and management. J Clin Pathol. 2008;61(11):1168–73.PubMed Singh PK, Buch HN. Adrenal incidentaloma: evaluation and management. J Clin Pathol. 2008;61(11):1168–73.PubMed
3.
go back to reference Hiroi N, Sue M, Yoshihara A, Ichijo T, Yoshida-Hiroi M, Higa M, et al. Prevalence of adrenal masses in Japanese patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:71.PubMedPubMedCentral Hiroi N, Sue M, Yoshihara A, Ichijo T, Yoshida-Hiroi M, Higa M, et al. Prevalence of adrenal masses in Japanese patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:71.PubMedPubMedCentral
4.
go back to reference Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006;29(4):298–302.PubMed Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006;29(4):298–302.PubMed
5.
go back to reference Vassiliadi DA, Tsagarakis S. Endocrine incidentalomas--challenges imposed by incidentally discovered lesions. Nat Rev Endocrinol. 2011;7(11):668–80.PubMed Vassiliadi DA, Tsagarakis S. Endocrine incidentalomas--challenges imposed by incidentally discovered lesions. Nat Rev Endocrinol. 2011;7(11):668–80.PubMed
6.
go back to reference Paschou SA, Vryonidou A, Goulis DG. Adrenal incidentalomas: a guide to assessment, treatment and follow-up. Maturitas. 2016;92:79–85.PubMed Paschou SA, Vryonidou A, Goulis DG. Adrenal incidentalomas: a guide to assessment, treatment and follow-up. Maturitas. 2016;92:79–85.PubMed
7.
go back to reference Sydney GI, Ioakim KJ, Paschou SA. Insulin resistance and adrenal incidentalomas: a bidirectional relationship. Maturitas. 2019;121:1–6.PubMed Sydney GI, Ioakim KJ, Paschou SA. Insulin resistance and adrenal incidentalomas: a bidirectional relationship. Maturitas. 2019;121:1–6.PubMed
8.
go back to reference Muscogiuri G, De Martino MC, Negri M, Pivonello C, Simeoli C, Orio F, et al. Adrenal mass: insight into pathogenesis and a common link with insulin resistance. Endocrinology. 2017;158(6):1527–32.PubMed Muscogiuri G, De Martino MC, Negri M, Pivonello C, Simeoli C, Orio F, et al. Adrenal mass: insight into pathogenesis and a common link with insulin resistance. Endocrinology. 2017;158(6):1527–32.PubMed
9.
go back to reference Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009;161(4):513–27.PubMed Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009;161(4):513–27.PubMed
10.
go back to reference Cyranska-Chyrek E, Szczepanek-Parulska E, Olejarz M, Ruchala M. Malignancy risk and hormonal activity of adrenal Incidentalomas in a large cohort of patients from a single tertiary reference center. Int J Environ Res Public Health. 2019;16(10):1872. Cyranska-Chyrek E, Szczepanek-Parulska E, Olejarz M, Ruchala M. Malignancy risk and hormonal activity of adrenal Incidentalomas in a large cohort of patients from a single tertiary reference center. Int J Environ Res Public Health. 2019;16(10):1872.
11.
go back to reference Di Dalmazi G, Pasquali R, Beuschlein F, Reincke M. Subclinical hypercortisolism: a state, a syndrome, or a disease? Eur J Endocrinol. 2015;173(4):M61–71.PubMed Di Dalmazi G, Pasquali R, Beuschlein F, Reincke M. Subclinical hypercortisolism: a state, a syndrome, or a disease? Eur J Endocrinol. 2015;173(4):M61–71.PubMed
12.
go back to reference Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601–10.PubMed Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med. 2007;356(6):601–10.PubMed
13.
go back to reference Ribeiro Cavalari EM, de Paula MP, Arruda M, Carraro N, Martins A, de Souza K, et al. Nonfunctioning adrenal incidentaloma: a novel predictive factor for metabolic syndrome. Clin Endocrinol (Oxf). 2018;89(5):586–95. Ribeiro Cavalari EM, de Paula MP, Arruda M, Carraro N, Martins A, de Souza K, et al. Nonfunctioning adrenal incidentaloma: a novel predictive factor for metabolic syndrome. Clin Endocrinol (Oxf). 2018;89(5):586–95.
14.
go back to reference Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, Del Viscovo L, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab. 2000;85(4):1440–8.PubMed Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, Del Viscovo L, et al. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. J Clin Endocrinol Metab. 2000;85(4):1440–8.PubMed
15.
go back to reference Moraes AB, Cavalari EMR, de Paula MP, Arruda M, Curi DSC, Leitao RA, et al. Evaluation of body composition using dual-energy X-ray absorptiometry in patients with non-functioning adrenal incidentalomas and an intermediate phenotype: is there an association with metabolic syndrome? J Endocrinol Invest. 2019;42(7):797–807.PubMed Moraes AB, Cavalari EMR, de Paula MP, Arruda M, Curi DSC, Leitao RA, et al. Evaluation of body composition using dual-energy X-ray absorptiometry in patients with non-functioning adrenal incidentalomas and an intermediate phenotype: is there an association with metabolic syndrome? J Endocrinol Invest. 2019;42(7):797–807.PubMed
16.
go back to reference Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171(1):201–4.PubMed Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998;171(1):201–4.PubMed
17.
go back to reference Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR. Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol. 2000;175(5):1411–5.PubMed Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR. Delayed enhanced CT of lipid-poor adrenal adenomas. AJR Am J Roentgenol. 2000;175(5):1411–5.PubMed
18.
go back to reference Bharwani N, Rockall AG, Sahdev A, Gueorguiev M, Drake W, Grossman AB, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR Am J Roentgenol. 2011;196(6):W706–14.PubMed Bharwani N, Rockall AG, Sahdev A, Gueorguiev M, Drake W, Grossman AB, et al. Adrenocortical carcinoma: the range of appearances on CT and MRI. AJR Am J Roentgenol. 2011;196(6):W706–14.PubMed
19.
go back to reference Sadler C, Goldfarb M. Risk estimator for adrenal tumor functionality. World J Surg. 2014;38(8):2019–24.PubMed Sadler C, Goldfarb M. Risk estimator for adrenal tumor functionality. World J Surg. 2014;38(8):2019–24.PubMed
20.
go back to reference Sbardella E, Minnetti M, D'Aluisio D, Rizza L, Di Giorgio MR, Vinci F, et al. Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas. Eur J Endocrinol. 2018;178(5):501–11.PubMed Sbardella E, Minnetti M, D'Aluisio D, Rizza L, Di Giorgio MR, Vinci F, et al. Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas. Eur J Endocrinol. 2018;178(5):501–11.PubMed
21.
go back to reference Araujo-Castro M, Sampedro Nunez MA, Marazuela M. Autonomous cortisol secretion in adrenal incidentalomas. Endocrine. 2019;64(1):1–13.PubMed Araujo-Castro M, Sampedro Nunez MA, Marazuela M. Autonomous cortisol secretion in adrenal incidentalomas. Endocrine. 2019;64(1):1–13.PubMed
22.
go back to reference Terzolo M, Pia A, Ali A, Osella G, Reimondo G, Bovio S, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87(3):998–1003.PubMed Terzolo M, Pia A, Ali A, Osella G, Reimondo G, Bovio S, et al. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002;87(3):998–1003.PubMed
23.
go back to reference Reincke M, Fassnacht M, Vath S, Mora P, Allolio B. Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res. 1996;22(4):757–61.PubMed Reincke M, Fassnacht M, Vath S, Mora P, Allolio B. Adrenal incidentalomas: a manifestation of the metabolic syndrome? Endocr Res. 1996;22(4):757–61.PubMed
24.
go back to reference Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T. The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf). 2001;54(6):797–804. Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T. The improvement of insulin resistance in patients with adrenal incidentaloma by surgical resection. Clin Endocrinol (Oxf). 2001;54(6):797–804.
25.
go back to reference Muscogiuri G, Sorice GP, Prioletta A, Mezza T, Cipolla C, Salomone E, et al. The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship? Clin Endocrinol (Oxf). 2011;74(3):300–5. Muscogiuri G, Sorice GP, Prioletta A, Mezza T, Cipolla C, Salomone E, et al. The size of adrenal incidentalomas correlates with insulin resistance. Is there a cause-effect relationship? Clin Endocrinol (Oxf). 2011;74(3):300–5.
26.
go back to reference Araujo-Castro M, Robles Lazaro C, Parra Ramirez P, Cuesta Hernandez M, Sampedro Nunez MA, Marazuela M. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences? Endocrine. 2019;66(3):650–9.PubMed Araujo-Castro M, Robles Lazaro C, Parra Ramirez P, Cuesta Hernandez M, Sampedro Nunez MA, Marazuela M. Cardiometabolic profile of non-functioning and autonomous cortisol-secreting adrenal incidentalomas. Is the cardiometabolic risk similar or are there differences? Endocrine. 2019;66(3):650–9.PubMed
27.
go back to reference Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273–85.PubMed Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol. 2003;149(4):273–85.PubMed
28.
go back to reference Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003;138(5):424–9.PubMed Grumbach MM, Biller BM, Braunstein GD, Campbell KK, Carney JA, Godley PA, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Ann Intern Med. 2003;138(5):424–9.PubMed
29.
go back to reference Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian society of endocrinology. J Clin Endocrinol Metab. 2000;85(2):637–44.PubMed Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian society of endocrinology. J Clin Endocrinol Metab. 2000;85(2):637–44.PubMed
30.
go back to reference Morelli V, Masserini B, Salcuni AS, Eller-Vainicher C, Savoca C, Viti R, et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf). 2010;73(2):161–6. Morelli V, Masserini B, Salcuni AS, Eller-Vainicher C, Savoca C, Viti R, et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin Endocrinol (Oxf). 2010;73(2):161–6.
31.
go back to reference Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011;96(5):1223–36.PubMed Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab. 2011;96(5):1223–36.PubMed
32.
go back to reference Paschou SA, Kandaraki E, Dimitropoulou F, Goulis DG, Vryonidou A. Subclinical Cushing's syndrome in patients with bilateral compared to unilateral adrenal incidentalomas: a systematic review and meta-analysis. Endocrine. 2016;51(2):225–35.PubMed Paschou SA, Kandaraki E, Dimitropoulou F, Goulis DG, Vryonidou A. Subclinical Cushing's syndrome in patients with bilateral compared to unilateral adrenal incidentalomas: a systematic review and meta-analysis. Endocrine. 2016;51(2):225–35.PubMed
33.
go back to reference Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of adrenal Cushing's syndrome. J Clin Pathol. 2015;68(3):175–86.PubMed Duan K, Gomez Hernandez K, Mete O. Clinicopathological correlates of adrenal Cushing's syndrome. J Clin Pathol. 2015;68(3):175–86.PubMed
34.
go back to reference Tsatsoulis A. The role of insulin resistance/Hyperinsulinism on the rising trend of thyroid and adrenal nodular disease in the current environment. J Clin Med. 2018;7(3):37. Tsatsoulis A. The role of insulin resistance/Hyperinsulinism on the rising trend of thyroid and adrenal nodular disease in the current environment. J Clin Med. 2018;7(3):37.
35.
go back to reference Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, Bancos I, et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight. 2017;2(8):e93136. Arlt W, Lang K, Sitch AJ, Dietz AS, Rhayem Y, Bancos I, et al. Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism. JCI Insight. 2017;2(8):e93136.
36.
go back to reference Dennedy MC, Annamalai AK, Prankerd-Smith O, Freeman N, Vengopal K, Graggaber J, et al. Low DHEAS: a sensitive and specific test for the detection of subclinical Hypercortisolism in adrenal Incidentalomas. J Clin Endocrinol Metab. 2017;102(3):786–92.PubMed Dennedy MC, Annamalai AK, Prankerd-Smith O, Freeman N, Vengopal K, Graggaber J, et al. Low DHEAS: a sensitive and specific test for the detection of subclinical Hypercortisolism in adrenal Incidentalomas. J Clin Endocrinol Metab. 2017;102(3):786–92.PubMed
Metadata
Title
The prevalence and characteristics of non-functioning and autonomous cortisol secreting adrenal incidentaloma after patients’ stratification by body mass index and age
Authors
Ana Podbregar
Andrej Janez
Katja Goricar
Mojca Jensterle
Publication date
01-12-2020
Publisher
BioMed Central
Keywords
Obesity
Obesity
Published in
BMC Endocrine Disorders / Issue 1/2020
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-020-00599-0

Other articles of this Issue 1/2020

BMC Endocrine Disorders 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.